• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Montagu and Kohlberg to Acquire Teleflex Medical OEM in a Carve-out Transaction

    12/9/25 9:20:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email

    Leading Medical Device Designer & Manufacturer to Operate as Independent Company Following Closing of Transaction

    Montagu and Kohlberg, two leading middle-market private equity firms, today announced that they have entered into a definitive agreement to acquire Teleflex Medical OEM (the "Company") from Teleflex Incorporated (NYSE:TFX) for $1.5 billion in a carve-out transaction.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208550931/en/

    For over 40 years, Teleflex Medical OEM has developed and supplied custom-engineered interventional catheter components and sub-assemblies, as well as surgical fibers and sutures, used across fast-growing treatment areas – including structural heart, neurovascular, electrophysiology and urology – that rely on advanced materials and precision manufacturing to improve surgical outcomes and patients' lives. With seven state-of-the-art facilities across the U.S., Mexico, and Ireland, the Company leverages its complex extrusion expertise, breadth of offering, and vertically integrated operating model to support a blue-chip customer base of medical device companies worldwide.

    Following the closing of the transaction, which is expected in the second half of 2026 subject to customary regulatory approvals and other closing conditions, the Company will operate as an independent, global contract developer and manufacturer ideally positioned to bring innovative solutions to market at pace, with the strategic focus and operational flexibility to scale its model. Greg Stotts, who joined Teleflex in 2006 and currently serves as the Company's President and General Manager, will become Chief Executive Officer of the Company at that time, bringing over three decades of industry sales, marketing, sales operations, and manufacturing experience to his new role.

    Mr. Stotts said: "This is a momentous milestone for our team and our customers, and we are excited to work with the Montagu and Kohlberg team to shape the future of Teleflex Medical OEM. As a focused, independent company backed by experienced healthcare investors, we will accelerate investment in innovation, quality systems and capacity while continuing to deliver the reliability and engineering depth our customers expect."

    Montagu and Kohlberg bring leading track records with decades of experience investing in healthcare products and services. The firms' complementary carve-out and value creation expertise will help to ensure Teleflex Medical OEM seamlessly transitions to an independent company while accelerating its growth by expanding its customer base, investing in innovation, people, processes and capabilities.

    Adrien Sassi, Partner at Montagu, added: "We have followed Teleflex Medical OEM for several years, giving us real insight into the caliber of the organization and the opportunity that lies ahead as an independent company. Over the last decade, Teleflex Medical OEM has built a reputation as a leading strategic supplier in the global medtech value chain, known for its engineering support, reliability, and quality. Working with Kohlberg, we look forward to leveraging our carve-out expertise, built through decades of transaction experience, and our strong track record in driving growth acceleration in medical device platforms, to support Greg and his team in unlocking the full potential of the company."

    Matt Jennings, Operating Partner at Kohlberg, will assume the role of Chairman of the Company upon closing of the transaction. Mr. Jennings commented: "Medical device companies are increasingly under pressure to optimize their portfolios and consolidate supply chains to create value for their patients and shareholders. Teleflex Medical OEM has proven itself as a differentiated, integrated, and compliant business uniquely positioned to create long-term mutually beneficial contract development and manufacturing partnerships with customers. We look forward to supporting Greg and the entire Teleflex Medical OEM team to create a bright future for all Company stakeholders as the business scales."

    "Teleflex Medical OEM is an exceptional platform trusted by its customers for its quality, service and delivery," added Chris Anderson, Senior Partner of Kohlberg. "The Company is ideally suited to benefit from Kohlberg's expertise supporting market-leading healthcare platforms, drawing on our deep network of operating executives and our ecosystem of investments and industry relationships. We look forward to working with our partners at Montagu, and together we are confident that Teleflex Medical OEM will thrive as a standalone platform focused on delivering maximum value to its customers."

    Raymond James acted as exclusive financial advisor, and Kirkland & Ellis and Ropes & Gray served as legal counsels to Montagu and Kohlberg.

    About Teleflex Medical OEM

    Teleflex Medical OEM is a leading contract developer and manufacturer of custom-engineered interventional catheter components and sub-assemblies, as well as surgical fibers and sutures. With seven sites across the U.S., Mexico, and Ireland, the Company combines deep materials expertise with vertically integrated manufacturing and dedicated EPIC design centers to help customers bring high-performance medical devices to market.

    About Montagu

    Montagu is a leading mid-market private equity firm, committed to finding and growing businesses that make the world work. Focusing on businesses with a must-have product or service in a structurally growing marketplace, Montagu brings proven growth capabilities to help companies achieve their ambitions and unlock their full potential. Montagu specializes in carve-out and other first-time buyout investments and has deep expertise in five priority sectors: Healthcare, Financial Sector Services, Critical Data, Digital Infrastructure and Education. ESG forms an integral part of its strategy, and its commitment to responsible investment is fully integrated into its investment and value-creation process. Montagu has €14 billion of assets under management.

    For more information, please visit www.montagu.com.

    About Kohlberg

    Founded in 1987, Kohlberg is a leading U.S. middle market private equity firm based in Mount Kisco, New York. The firm invests in leading healthcare and services companies characterized by strong market positions, recurring revenue streams and resilient end markets, which it identifies through rigorous thematic research grounded in its White Paper Program. Leveraging its team of investment and operating professionals, Kohlberg works with management teams to accelerate growth, enhance operational excellence and create value. As of September 30, 2025, Kohlberg manages approximately $17 billion on behalf of investors globally.

    For more information, please visit www.kohlberg.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251208550931/en/

    Media enquiries – Montagu

    Greenbrook: James Madsen, Cecilie Oerting

    +44 20 7952 2000 | [email protected]



    Media enquiries – Kohlberg

    Gasthalter & Co.: Amanda Shpiner, Jonathan Warren

    +1 212-257-4170 | [email protected]

    Get the next $TFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/1/2024$205.00 → $245.00Neutral → Overweight
    Piper Sandler
    12/4/2023$261.00Equal-Weight → Overweight
    Morgan Stanley
    6/21/2023Buy → Hold
    Needham
    More analyst ratings

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Montagu and Kohlberg to Acquire Teleflex Medical OEM in a Carve-out Transaction

    Leading Medical Device Designer & Manufacturer to Operate as Independent Company Following Closing of Transaction Montagu and Kohlberg, two leading middle-market private equity firms, today announced that they have entered into a definitive agreement to acquire Teleflex Medical OEM (the "Company") from Teleflex Incorporated (NYSE:TFX) for $1.5 billion in a carve-out transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208550931/en/ For over 40 years, Teleflex Medical OEM has developed and supplied custom-engineered interventional catheter components and sub-assemblies, as well as surgical fibers and sutures, used acros

    12/9/25 9:20:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion

    WAYNE, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has entered into definitive agreements to sell the company's Acute Care, Interventional Urology and OEM businesses to two buyers, Intersurgical® Ltd with respect to Acute Care and Interventional Urology, and Montagu and Kohlberg with respect to OEM, for a combined total of $2.03 billion in cash, subject to certain closing adjustments. "Over the past year, we have executed a clear strategy to optimize our portfolio and best position Teleflex for the future, with a focus on driving growth across our core critical care and high acuity hospital

    12/9/25 9:04:01 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex to Present at the Jefferies Global Healthcare Conference in London

    WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE:TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. (GMT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interve

    11/14/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teleflex downgraded by BofA Securities with a new price target

    BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously

    3/4/25 7:44:32 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously

    2/28/25 7:34:55 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex downgraded by Raymond James

    Raymond James downgraded Teleflex from Outperform to Mkt Perform

    2/28/25 7:34:03 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    SEC Filings

    View All

    Teleflex Incorporated filed SEC Form 8-K: Regulation FD Disclosure

    8-K - TELEFLEX INC (0000096943) (Filer)

    12/9/25 5:08:17 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Teleflex Incorporated

    10-Q - TELEFLEX INC (0000096943) (Filer)

    11/6/25 10:01:33 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TELEFLEX INC (0000096943) (Filer)

    11/6/25 7:00:42 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Financials

    Live finance-specific insights

    View All

    Teleflex Announces Quarterly Dividend

    WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2025, to shareholders of record at the close of business on November 14, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiol

    11/6/25 6:45:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook

    WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP revenue of $913.0, up 19.4% compared to the prior year periodAdjusted revenue of $892.9 million, up 16.8% compared to the prior year period, and up 15.3% on an adjusted constant currency basis1GAAP diluted EPS from continuing operations of $(9.24), compared to $2.36 in the prior year periodAdjusted diluted EPS from continuing operations of $3.67, compared to $3.49 in the prior year period 2025 guidance summary  Narrowing GAAP revenue growth guidance range to 9.10% to 9.60% Lo

    11/6/25 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details

    WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 6, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609

    10/16/25 4:30:10 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    View All

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

    WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

    2/27/25 6:36:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/14/24 1:28:29 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/8/24 10:29:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    2/14/24 10:04:36 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care